查找临床试验
已按「系统性红斑狼疮」检索，对应国际通用词 systemic lupus erythematosus
共找到 286 项正在招募的试验
数据更新于 23:04，每 5 分钟自动同步A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
China
年龄 18 Years – 65 Years
China Immunotech (Beijing) Biotechnology Co., Ltd.
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
China
年龄 18 Years – 不限
Tongji Hospital
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Peking University People's Hospital
Deciphering the Genetic Architecture of Autoimmune Diseases
United States、Peru
年龄 18 Years – 115 Years
National Human Genome Research Institute (NHGRI)
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Beijing GoBroad Hospital
" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
Egypt
年龄 18 Years – 60 Years
South Valley University
Anifrolumab Malignancy and Serious Infections Study
Denmark、France、Germany、Spain
年龄 18 Years – 130 Years
AstraZeneca
CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
South Korea
年龄 不限 – 25 Years
Seoul National University Hospital
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Germany
年龄 18 Years – 130 Years
AstraZeneca
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
Sweden
年龄 18 Years – 100 Years
Region Stockholm
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
United States、Brazil、Canada、France、Italy 等 12 国
年龄 5 Years – 17 Years
Hoffmann-La Roche